Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down

Use of a Label-Free Platform in a preclinical Contract Research Organization Environment
Bookmark and Share

Caliper Life Sciences

Caliper Discovery Alliances & Services (CDAS) is a Contract Research Organization offering comprehensive in vitro and in vivo preclinical contract research services. Their offering is articulated around different platforms including Target Validation with the creation of transgenic animals, Assay Development, Screening, Safety Pharmacology, Biochemical and Functional cell based profiling, Drug Efficacy in disease models and non-invasive small animal Optical Imaging.

NovaScreen Biosciences, now part of CDAS, pioneered receptor profiling studies in the early 1990’s and has established a best in class safety pharmacology platform with a large number of GPCR binding assays. Functional studies are very complementary to affinity-based radioligand assays as they provide very valuable information on the way a drug interacts with a GPCR target.

Using CDAS GPCRFunctional™ programs, you can determine if a drug is an activator or an inhibitor or what its potency and efficacy are for a given GPCR target. Understanding drug functionality is also an important benefit of functional studies and you can for example identify allosteric modulators that are generally difficult to identify using orthosteric ligand-based radioligand binding assays.

Further Information

Related Content

Caliper Life Sciences and IntegenX Enter License Agreement for Microfluidics Patent Portfolio
IntegenX and Caliper Life Sciences announced a license agreement providing IntegenX access to Caliper's microfluidics patent portfolio.
Friday, March 11, 2011
Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products
Caliper and Seegene partner to deliver innovative diagnostic panels on Caliper's LabChip® Dx platform.
Tuesday, January 18, 2011
Caliper Life Sciences Completes Previously Announced CRi Acquisition
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of products and services for drug discovery research, announces that it has completed the acquisition of privately-held Cambridge Research & Instrumentation, Inc. (CRi) pursuant to the terms of the merger agreement previously announced on December 9, 2010.
Wednesday, December 22, 2010
Caliper Life Sciences to Acquire Cambridge Research & Instrumentation
Adds Proprietary Multiplexed In Vivo and Tissue Imaging Technology to Caliper's Leading Portfolio of Drug Discovery, Imaging and Diagnostics Solutions.
Friday, December 10, 2010
Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
Foundation purchases Caliper’s Staccato system to enable high throughput research processes.
Friday, May 29, 2009
Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Forms Alliance with Horizon Discovery
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.
Thursday, April 10, 2008
Caliper LS Awarded National Institute of Environmental Health Services Contract Valued to $7 Million
Caliper Discovery Alliances & Services to develop customized transgenic and knock-out mouse models.
Thursday, October 04, 2007
Caliper Life Sciences Introduces High Throughput RNA Assay for Gene Expression Studies
According to Company, the new assay assures integrity of RNA samples and offers improved throughput and walk-away time.
Thursday, September 13, 2007
Caliper Life Sciences Licenses Monogram Biosciences' Microfluidics Patents
Additional intellectual property portfolio to expand and strengthen Caliper Driven™ licensing program.
Thursday, May 03, 2007
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies
Pfizer, AstraZeneca and Momenta Pharmaceuticals purchase Caliper systems for In Vitro and In Vivo research efforts.
Wednesday, December 13, 2006
Caliper Continues Momentum with Expanded LabChip 3000 Sales
Currently 12 of the top 15 pharmaceutical companies actively use Caliper systems as key tools in their discovery efforts.
Friday, May 26, 2006
Caliper Life Sciences Aids the Sanger Institute's Protein Expression Project
The Wellcome Trust Sanger Institute has purchased the microfluidic-based LabChip® 90 Automated Electrophoresis System to quality control DNA and proteins.
Wednesday, April 05, 2006
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos